CL2004000545A1 - Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul - Google Patents

Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Info

Publication number
CL2004000545A1
CL2004000545A1 CL200400545A CL2004000545A CL2004000545A1 CL 2004000545 A1 CL2004000545 A1 CL 2004000545A1 CL 200400545 A CL200400545 A CL 200400545A CL 2004000545 A CL2004000545 A CL 2004000545A CL 2004000545 A1 CL2004000545 A1 CL 2004000545A1
Authority
CL
Chile
Prior art keywords
antagonist
profilaxis
endotheline
hypertension
pathological condition
Prior art date
Application number
CL200400545A
Other languages
English (en)
Inventor
G Mcmahon Amy E Rudolph Ellen
Original Assignee
Pharmacia Corp Sa Organizada B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp Sa Organizada B filed Critical Pharmacia Corp Sa Organizada B
Publication of CL2004000545A1 publication Critical patent/CL2004000545A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UNA COMBINACION DE UNO O MAS ANTAGONISTAS DE RECEPTORES DE LA ALDOSTERONA Y UNO O MAS ANTAGONISTAS DE RECEPTORES DE LA ENDOTELINA Y/O INHIBIDORES DE LA ECE SELECCIONADOS DE UN GRUPO ESPECIFICO DE COMPUESTOS QUE SE DESCRIBEN EN EL PRESENTE DOCUMENTO PARA EL TRATAMIENTO TERAPEUTICO Y/O PROFILAXIS PARA UNA CONDICION DE HIPERTENSION, ENFERMEDAD CARDIOVASCULAR, DISFUNCION RENAL, EDEMA, ENFERMEDAD CEREBROVASCULAR, O CONDICION PATOLOGICA DE INSULINOPATIA.
CL200400545A 2003-03-18 2004-03-17 Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul CL2004000545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45558003P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
CL2004000545A1 true CL2004000545A1 (es) 2005-01-28

Family

ID=33030025

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400545A CL2004000545A1 (es) 2003-03-18 2004-03-17 Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Country Status (4)

Country Link
US (1) US20040186083A1 (es)
CL (1) CL2004000545A1 (es)
TW (1) TW200503730A (es)
WO (1) WO2004082637A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
PT1706121E (pt) * 2004-01-12 2008-12-04 Solvay Pharm Bv Inibidores de endopeptidase neutra (nep) e endopeptidase humana solúvel (hsep) para profilaxia e tratamento de distúrbios neurodegenerativos
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ, インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AR052900A1 (es) * 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
ES2344800T3 (es) * 2005-02-18 2010-09-07 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y diureticos.
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
CA2652345A1 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea related applications
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US20090012012A1 (en) * 2007-07-05 2009-01-08 Jerome Cantor Intratracheal administration of endothelin-suppressing agents for the treatment of respiratory disorders
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
DE102011015142A1 (de) * 2011-03-17 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agens zur Prophylaxe und Behandlung altersassoziierter Krankheiten und Störungen sowie zur Verlängerung der Lebensdauer
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
EP2884988A4 (en) * 2012-08-17 2016-04-20 Father Flanagan S Boys Home Doing Business As Boy Town Nat Res Hospital RAC1 INHIBITORS FOR THE TREATMENT OF GLOMEROLARY ALPORT SYNDROME
KR20160003128A (ko) * 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
WO2017185142A1 (en) * 2016-04-29 2017-11-02 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating atrial fibrillation
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
AU2020296105A1 (en) 2019-06-21 2022-02-03 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Neutralizing antibodies to human endothelin
US20250144095A1 (en) * 2022-02-03 2025-05-08 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
AU725689B2 (en) * 1995-06-07 2000-10-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

Also Published As

Publication number Publication date
WO2004082637A2 (en) 2004-09-30
TW200503730A (en) 2005-02-01
WO2004082637A3 (en) 2007-05-10
US20040186083A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CL2004000545A1 (es) Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
UY28871A1 (es) Antagonistas del receptor de acetilcolina muscarinico
EA200600773A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
UY28598A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
TNSN07264A1 (en) Organic compounds
WO2004100871A3 (en) Combination of an aldosterone receptor antagonist and a renin inhibitor
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY2015029I1 (el) Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
CL2004000544A1 (es) Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
UY28417A1 (es) Antagonistas de los receptores muscarinicos de la acetilcolina
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
CL2007003198A1 (es) Compuestos diarilicos opcionalmente nitrogenados, antagonistas de los receptores opioides; composicion farmaceutica; y uso en el tratamiento de la obesidad.
UY28567A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
WO2007033140A3 (en) Prok2 antagonists and methods of use
BRPI0412255A (pt) tratamento da disfunção sexual masculina
UY28415A1 (es) Antagonistas de los receptores muscarinicos de la acetilcolina
UY28414A1 (es) Antagonistas de los receptores muscarinicos de la acetilcolina
CR7222A (es) Combinacion de un agonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa
UY28557A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
ECSP003823A (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelia duales